Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

The purpose of this protocol is to provide supervised and limited access to Therasphere® treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis who cannot be treated by surgical removal of the affected part of the liver. Patient response to treatment and any side effects of Therasphere® treatment will be examined.

Sex

All

Minimum age

19 Years

Inclusion Criteria:

* Confirmed diagnosis of primary or metastatic intrahepatic carcinoma
* The cancer must be unresectable with limited established treatment options
* ECOG Performance Status Score 0-2
* Age 19 years or older
* Able to comprehend and provide written informed consent

Exclusion Criteria:

* Any pre-treatment laboratory findings within 15 days of treatment demonstrating:
* Absolute granulocyte count ≤ 1,500/ul
* Platelet count ≤ 75,000/ul
* Serum creatinine \> 2.0 mg/dl
* Serum bilirubin ≥ 2.0 mg/dl
* Any of the following contraindications to angiography and selective visceral catheterization:
* History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine
* Bleeding, diathesis, not correctable by usual forms of therapy
* Severe peripheral vascular disease that would preclude catheterization
* Substantial venous shunt away from the liver
* Evidence of potential delivery of greater than 11 mCi (20 Gy absorbed dose) of radiation to the lungs on either 1) first Therasphere® administration; or 2) cumulative delivery of radiation to the lungs over multiple treatments
* Evidence of any detectable Tc-99 MAA flow to the stomach or duodenum, application of established angiographic techniques to stop such flow
* Significant extrahepatic disease representing an imminent life- threatening situation outcome
* Severe liver dysfunction or pulmonary insufficiency
* Active uncontrolled infection
* Significant underlying medical or psychiatric illness
* Pregnant women may not participate

• BACKGROUNDHoule S, Yip TK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH, Richmond-Cox K. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology. 1989 Sep;172(3):857-60. doi: 10.1148/radiology.172.3.2549567. PMID 2549567
• BACKGROUNDAndrews JC, Walker-Andrews SC, Juni JE, Warber S, Ensminger WD. Modulation of liver tumor blood flow with hepatic arterial epinephrine: a SPECT study. Radiology. 1989 Dec;173(3):645-7. doi: 10.1148/radiology.173.3.2813766. PMID 2813766
• BACKGROUNDWollner I, Knutsen C, Smith P, Prieskorn D, Chrisp C, Andrews J, Juni J, Warber S, Klevering J, Crudup J, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer. 1988 Apr 1;61(7):1336-44. doi: 10.1002/1097-0142(19880401)61:73.0.co;2-k. PMID 3345490
• BACKGROUNDZiessman HA, Thrall JH, Gyves JW, Ensminger WD, Niederhuber JE, Tuscan M, Walker S. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983 Oct;24(10):871-5. PMID 6225839
• BACKGROUNDNakamura H, Tanaka M, Oi H. Hepatic embolization from the common hepatic artery using balloon occlusion technique. AJR Am J Roentgenol. 1985 Jul;145(1):115-6. doi: 10.2214/ajr.145.1.115. No abstract available. PMID 3873830
• BACKGROUNDWellwood JM, Cady B, Oberfield RA. Treatment of primary liver cancer: response to regional chemotherapy. Clin Oncol. 1979 Mar;5(1):25-31. No abstract available. PMID 217565
• BACKGROUNDReed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer. 1981 Jan 15;47(2):402-9. doi: 10.1002/1097-0142(19810115)47:23.0.co;2-b.